| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3884772 | Kidney International | 2010 | 4 Pages |
Abstract
Hemodialysis patients are at increased risk of acquiring hepatitis B virus (HBV) infection. Administration of the standard HBV vaccine is suboptimal as a means of prevention because of an impaired seroconversion response in individuals with chronic kidney disease. Surquin and colleagues describe a novel vaccine adjuvant system that increases speed of seroconversion and duration of seroprotection compared with older vaccine formulations. However, its ability to improve overall seroconversion response remains unproven.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Katherine A. Barraclough, E. Geoffrey Playford,